Display Settings:

Format

Send to:

Choose Destination
We are sorry, but NCBI web applications do not support your browser and may not function properly. More information
Clin Cancer Res. 2010 Oct 15;16(20):4914-20. doi: 10.1158/1078-0432.CCR-10-0433. Epub 2010 Aug 11.

Targeting eukaryotic translation initiation factor 4E (eIF4E) in cancer.

Author information

  • 1Department of Urology, Helen Diller Family Comprehensive Cancer Center, School of Medicine, University of California, San Francisco, San Francisco, California, USA.

Abstract

Recent advances in understanding the role of eukaryotic translation initiator factor 4E (eIF4E) in tumorigenesis and cancer progression have generated significant interest in therapeutic agents that indirectly or directly target aberrant activation of eIF4E in cancer. Here, we address the general function of eIF4E in translation initiation and cancer, present evidence supporting its role in cancer initiation and progression, and highlight emerging therapeutics that efficiently target hyperactivated eIF4E. In doing so, we also highlight the major differences between these therapeutics that may influence their mechanism of action.

©2010 AACR.

PMID:
20702611
[PubMed - indexed for MEDLINE]
Free full text
PubMed Commons home

PubMed Commons

0 comments
How to join PubMed Commons

    Supplemental Content

    Full text links

    Icon for HighWire
    Loading ...
    Write to the Help Desk